论文部分内容阅读
[目的]探讨运用曲美他嗪治疗慢性心力衰竭对心肌的保护作用。[方法]将滕州市中心人民医院心内科收治的94例慢性心力衰竭患者随机分为对照组和试验组各47例,对照组用标准化治疗,试验组则是在对照组基础上联合曲美他嗪治疗。[结果]治疗后,均有较多患者心功能达到I级。两组心功能分级同治疗前比较,差异均有统计学意义(P<0.01)。但治疗后两组心功能I+Ⅱ级的占比各为82.9%、65.9%,差异尚无统计学意义(P>0.05)。治疗后,试验组显效18例、有效25例、无效4例,临床总有效率为91.5%,对照组显效10例、有效27例、无效10例,临床总有效率为80.4%,总有效率差异有统计学意义(P<0.05)。治疗后,试验组血浆BNP水平、LVEDD、LVESD低于对照组,但LVEF高于对照组,6 min步行距离多于对照组,差异均有统计学意义(P<0.05)。[结论]在标准化治疗的基础上联合曲美他嗪,能够改善慢性心力衰竭患者心功能,实现保护心肌目的,改善患者预后。
[Objective] To explore the protective effect of trimetazidine on myocardium in patients with chronic heart failure. [Methods] Ninety-four patients with chronic heart failure admitted to Department of Cardiology, People’s Hospital of Tengzhou Central People’s Hospital were randomly divided into control group and experimental group, 47 cases in each group. The control group was treated with standardization. The experimental group was treated with trimetazidine Triazine treatment. [Results] After treatment, more patients had grade I heart function. The heart function grading of the two groups before treatment, the difference was statistically significant (P <0.01). However, after treatment, the two groups of I + Ⅱ grade of heart function accounted for 82.9%, 65.9%, the difference was not statistically significant (P> 0.05). After treatment, the experimental group markedly effective in 18 cases, effective in 25 cases, ineffective in 4 cases, the clinical total effective rate was 91.5%, the control group markedly effective in 10 cases, effective in 27 cases, ineffective in 10 cases, the clinical total effective rate was 80.4%, the total effective rate The difference was statistically significant (P <0.05). After treatment, the levels of plasma BNP, LVEDD and LVESD in the experimental group were lower than those in the control group, but the LVEF was higher in the experimental group than in the control group, and the walking distance was longer in 6 minutes than in the control group (P <0.05). [Conclusion] Combination of trimetazidine with standardized therapy can improve cardiac function in patients with chronic heart failure, achieve the purpose of protecting myocardium and improve the prognosis of patients.